GAITHERSBURG, MD.

— First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant — Phase 1/2 study will evaluate immunogenicity and safety Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate […]

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series Analysis of sera from primary vaccination series also showed cross-reactive functional antibodies to Alpha, Beta and Delta variants, all of which increased […]

– Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax’ recombinant nanoparticle COVID-19 vaccine – Filing for World Health Organization Emergency Use Listing expected in August 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for […]